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Abstract Grb14 belongs to the Grb7 family of adapter pro-
teins and was identi¢ed as a negative regulator of insulin signal
transduction. Its inhibitory e¡ect on the insulin receptor kinase
activity is controlled by a newly discovered domain called PIR.
To investigate the biochemical and biophysical characteristics of
this new domain, we cloned and puri¢ed recombinant PIR-SH2,
PIR, and SH2 domains. The isolated PIR and PIR-SH2 do-
mains were physiologically active and inhibited insulin-induced
reinitiation of meiosis in the Xenopus oocytes system. However,
NMR experiments on 15N-labelled PIR revealed that it did not
present secondary structure. These results suggest that the PIR
domain belongs to the growing family of intrinsically unstruc-
tured proteins.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Molecular adapters are involved in multiple protein/protein
and protein/phospholipid interactions required in cascade ac-
tivation. This makes them essential components of signal
transduction pathways.
A new family of adapters has recently emerged, the Grb7
family composed of Grb7, Grb10 and Grb14 [1]. All members
of this family are characterized by several conserved domains:
an N-terminal proline rich region, a Ras-associated-like do-
main, a pleckstrin homology (PH) domain, and a C-terminal
Src homology 2 (SH2) domain. Like other adapter molecules,
Grb7 family members have been shown to interact with a
variety of cell surface receptors and also with other signaling
proteins. Most of these interactions are mediated by their SH2
domain in a phosphotyrosine-dependent manner [2].
To date, limited information is available concerning the
biological roles of Grb7, Grb10 and Grb14.
b Various studies have suggested the importance of Grb7 in
tumor progression [3,4] and in the regulation of cell migra-
tion [5,6].
b Grb10 can be found as six di¡erent isoforms, whose func-
tions are not yet fully elucidated. Grb10 can bind to Raf
and MEK, and thus is likely to be implicated in the MAP
Kinase cascade and in cell proliferation [7].
b Grb14 is the most recently identi¢ed member of the Grb7
family of adapters. It is speci¢cally expressed in insulin-
sensitive tissues. Furthermore, insulin induces Grb14 bind-
ing to the insulin receptor (IR) in vivo in rat liver, suggest-
ing that it is a physiological insulin signaling e¡ector [8].
Overexpression of Grb14 in CHO-IR cells inhibits insulin-
stimulated DNA and glycogen synthesis or tyrosine phos-
phorylation of proteins [8,9].
In vitro tyrosine kinase assays have shown that the Grb7
family members inhibit the IR catalytic activity, and that
Grb14 is the most potent inhibitor [10,11]. For all three
Grbs, the inhibitory action on the IR kinase activity is medi-
ated by a new interaction domain located between the SH2
and PH domains called either BPS (between PH and SH2) [12]
or PIR (phosphorylated insulin receptor interacting region)
[8,13]. PIR speci¢cally binds to the regulatory kinase loop
of the IR. This domain is highly conserved among the mem-
bers of the Grb7 family and does not show any similarity with
any other known protein interaction domain. To date, only
one other partner of the PIR domain has been described, the
protein kinase Cj interacting protein (ZIP) [14].
The three Grbs members are all able to bind to the acti-
vated IR through both their PIR and SH2 domains, but in-
terestingly, the relative importance of the two domains de-
pends on the member of the Grb7 family and the receptor
tyrosine kinase considered. For Grb10, the PIR and SH2 do-
mains interact equally with the IR, while PIR seems to be the
major binding domain with the insulin-like growth factor re-
ceptor (IGF-R) [12,15,16]. By contrast, the SH2 domain of
Grb7 is su⁄cient for the interaction with IR [13]. In the case
of Grb14, the interaction with IR is mainly due to the PIR
domain [8,11]. Therefore the di¡erential binding of PIR and
SH2 domains should be a determinant for the speci¢city in
Grbs’ interactions with receptor tyrosine kinase.
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SH2 domains have been studied extensively; over a hun-
dred structures exist in the PDB [17]. However, until now
there is no structural data for the PIR domain. This study
is the ¢rst biophysical analysis of the PIR domain. Using
heteronuclear NMR spectroscopy we describe the unstruc-
tured nature of PIR. Xenopus oocytes have been used as an
experimental model for activity analysis of recombinant PIR
domain. In spite of the lack of ordered structure, PIR is phys-
iologically active. Taken together, these results suggest that
PIR belongs to the expanding family of intrinsically unstruc-
tured proteins (IUPs).
2. Materials and methods
2.1. Cloning and expression of recombinant PIR and PIR-SH2 domains
of Grb14
Constructs for the PIR (encoding residues 361^435), PIR-SH2 (en-
coding residues 361^538) and SH2 (encoding residues 430^538) do-
mains of Grb14 were subcloned into expression vector pET28b (No-
vagen). All constructs were veri¢ed by DNA sequencing. Escherichia
coli strain BL21-DE3 was transformed with plasmids and cultures
were grown in Luria broth with 30 Wg ml31 kanamycin (Sigma) at
37‡C to an OD600nm of 1.0 for the PIR and PIR-SH2 domains, and to
0.6 for the SH2 domain. Protein expression was induced by addition
of 0.1 mM ¢nal IPTG (Sigma) for 4 h at 28‡C. Cells were harvested
by centrifugation at 8000Ug for 30 min and immediately frozen at
380‡C.
2.2. Puri¢cation and NMR sample preparation
2.2.1. Puri¢cation of recombinant PIR-SH2 domain of Grb14. All
puri¢cation procedures were carried out at 4‡C. Cells (9 g) were sus-
pended in 60 ml of 50 mM Tris^HCl bu¡er pH 8.8 containing 500
mM NaCl, 1% (v/v) Triton X-100, 1 mM phenylmethylsulfonyl £uo-
ride (PMSF), 1 mM dithiothreitol (DTT), and were disrupted by
sonication. CaCl2 to a ¢nal concentration of 0.6 mM was added to
remove DNA, followed by centrifugation at 8000Ug. The supernatant
was dialyzed against a 50 mM Tris^HCl bu¡er pH 8.0 containing 500
mM NaCl, 0.1% (v/v) Triton X-100, 1 mM DTT and 5 mM EDTA to
remove CaCl2, and then against a 50 mM Tris^HCl bu¡er pH 8.0
with 1 mM DTT (bu¡er A). The dialyzed supernatant was loaded
onto a Sepharose high performance Q column (Pharmacia Biotech)
equilibrated with bu¡er A. The £ow-through fractions were recovered
and applied onto a Sepharose high performance SP column (Pharma-
cia Biotech) equilibrated with bu¡er A. Proteins were eluted with a
linear gradient (0^0.2 M) of NaCl in bu¡er A (total volume 180 ml) at
a £ow rate of 1 ml min31. The resulting fractions were chromato-
graphed on a gel-¢ltration column (Sephacryl S-100, Pharmacia Bio-
tech) equilibrated with a 50 mM succinate bu¡er pH 6.5 containing
150 mM NaCl and 1 mM DTT at a £ow rate of 0.3 ml min31. The
PIR-SH2 fractions were concentrated to about 10 mg ml31 (0.5 mM)
and stored at 380‡C.
2.2.2. Puri¢cation of recombinant PIR domain of Grb14. Cells (5 g)
were suspended in 20 ml of 50 mM glycine bu¡er pH 9.5 containing
500 mM NaCl, 1% (v/v) Triton X-100, 1 mM PMSF, 1 mM DTT, and
were disrupted by sonication. CaCl2 to a ¢nal concentration of 0.6
mM was added to remove DNA followed by centrifugation at
8000Ug. The supernatant was dialyzed against a 50 mM glycine bu¡-
er pH 9.5 containing 500 mM NaCl, 0.1% (v/v) Triton X-100, 5 mM
EDTA to remove CaCl2, and then against a 50 mM Tris^HCl bu¡er
pH 8.0 with 50 mM NaCl, 0.1% (v/v) Triton X-100, 5 mM EDTA.
The dialyzed supernatant was diluted three-fold in 50 mM Tris^HCl
bu¡er pH 8.0 (bu¡er A) and applied onto a cation exchange high
performance SP column (Pharmacia Biotech). Proteins were eluted
with a linear gradient (0^0.35 M) of NaCl in bu¡er A (total volume
140 ml). PIR fractions were further puri¢ed on a gel-¢ltration column
(Sephacryl S-100, Pharmacia Biotech) equilibrated with bu¡er A at a
£ow rate of 0.5 ml min31. PIR was stored at 4‡C at about 5 mg ml31
in 50 mM Tris^HCl pH 8.0, 1 mM TCEP (Tris-(2-carboxyethyl)phos-
phine).
2.2.3. Puri¢cation of recombinant SH2 domain of Grb14. Cells (4 g)
were suspended in 20 ml of 50 mM Tris^HCl bu¡er pH 8.5 containing
500 mM NaCl, 0.1% (v/v) Triton X-100, 1 mM PMSF, 5 mM EDTA,
5 mM DTT, and were disrupted by sonication. Cells debris were
pelleted and the supernatant was diluted to a ¢nal volume of 200
ml in 50 mM Tris^HCl bu¡er pH 8.0 with 1 mM DTT (bu¡er A)
before being loaded onto a Sepharose high performance Q column
(Pharmacia Biotech) equilibrated with bu¡er A. Proteins were eluted
with a linear gradient (0.05^0.150 M) of NaCl in bu¡er A (total
volume 180 ml) at a £ow rate of 1 ml min31. The resulting fractions
were chromatographed on a gel-¢ltration column (Sephacryl S-100,
Pharmacia Biotech) equilibrated with a 50 mM Tris^HCl bu¡er pH
8.5 containing 100 mM NaCl and 1 mM DTT at £ow rate of 0.3 ml
min31. The yield was 20 mg per liter of culture. The SH2 fractions
were concentrated to about 10 mg ml31 (0.5 mM) and stored at
380‡C.
Every step of puri¢cation was veri¢ed by sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE) according to the
Laemmli method.
Proteins concentrations were determined using calculated extinction
coe⁄cients. Proteins were characterized using N-terminal sequence
determination.
For NMR experiments, 15N-labelled PIR and PIR-SH2 samples
were obtained by growing the corresponding strains in Martek-9N
medium (Martek Inc.) containing 30 Wg ml31 of kanamycin and sup-
plemented with 2 g l31 of 15N-celtone. The labelled proteins were
puri¢ed as described above, and concentrated at about 0.5 mM in
50 mM potassium phosphate bu¡er pH 7.0 containing 10% D2O.
The yield of production of the 15N-labelled proteins was the same
as for the unlabelled ones, i.e. 15 mg of pure PIR-SH2 and 5 mg of
pure PIR for 1 l 15N-labelled medium.
2.3. NMR experiments
NMR samples were prepared in H20/2H2O (90/10). The 15N-la-
belled PIR concentration was circa 1 mM (pH 5.0). 1D, 2D and 3D
experiments were recorded at 300 K on a Bruker 600 MHz Avance
spectrophotometer equipped with a triple resonance inverse probe. 2D
homonuclear NOESY and TOCSY were recorded with the identical
spectral width of 7800 Hz in both dimensions, using mixing times of
200 and 55 ms, respectively. A 2D 15N^1H echo/antiecho heteronu-
clear single quantum correlation (HSQC) [18,19] was recorded with
spectral widths of 3000 Hz and 1580 Hz in the 1H and 15N dimen-
sions, respectively. 3D NOESY-HSQC [20] and 3D TOCSY-HSQC
[21] were recorded with spectral widths of 4800, 2400, 8400 Hz, re-
spectively for amide 1H, 15N and 1H dimensions, and mixing times of
200 ms (NOESY) and 55 ms (TOCSY). Heteronuclear 15N^1H NOE
cross-relaxation rates were measured [22,23]. Two refocused reverse
2D INEPT spectra were recorded in an interleaved manner, either
with or without proton saturation during the relaxation delay (4 s)
prior to the starting 90 15N pulse. Apart from the proton saturation,
all other parameters were identical in both experiments. Data process-
ing was done with FELIX (MSI, San Diego, CA, USA).
2.4. Xenopus oocyte studies
After anesthesia with MS 222 (1 g l31, Sandoz), Xenopus laevis
ovarian lobes were surgically removed and placed in modi¢ed OR2
medium, lacking potassium (82.5 mM NaCl, 1 mM MgCl2, 1 mM
CaCl2, 1 mM Na2HPO4, 5 mM HEPES, adjusted to pH 7.4), supple-
mented with streptomycin/penicillin (50 Wg ml31, Eurobio), tetracy-
cline (50 Wg ml31, Sigma), sodium pyruvate (225 Wg ml31, Sigma) and
soybean trypsin inhibitor (30 Wg ml31, Sigma). Full grown stage VI X.
laevis oocytes were obtained by defolliculation using a 1 h treatment
with collagenase A (1 mg ml31, Boehringer Mannheim) and achieved
by manual dissection. Oocytes were kept at 19‡C in modi¢ed OR2
medium. Oocytes were treated with insulin 1WM. Microinjections of
PIR, PIR-SH2 and SH2 domains were processed in the equatorial
region 1h before insulin stimulation. Controls were performed without
protein injection before insulin stimulation. Germinal vesicle break-
down (GVBD) was determined by the appearance of a white spot at
the center of the animal pole 20 h after insulin treatment. For each
injection the experiment was performed on at least two di¡erent
batches of 20 oocytes each.
3. Results
3.1. Production of the recombinant proteins
To study the binding and inhibitory properties of the Grb14
protein, its PIR, PIR-SH2 and SH2 domains were overex-
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pressed and puri¢ed. Several constructs using fusions or tags
were tested but they all led to either unexpressed or insoluble
proteins. Consequently, all three domains were expressed in
their native forms. The HCA (hydrophobic cluster analysis)
program [24] and sequence alignment analysis were used to
optimize selection of the domains. Subsequently the recombi-
nant proteins expressed in E. coli were soluble.
Some puri¢cation problems were encountered with the PIR
and PIR-SH2 domains, as PIR is extremely basic (pI 9.86)
causing unspeci¢c binding with DNA. To overcome this di⁄-
culty, precipitation of DNA by CaCl2 (T. Rabilloux, personal
communication) was performed, allowing the puri¢cation of
PIR and PIR-SH2 in only two steps with a yield of 4.5 and 15
mg, respectively, of pure protein per liter of culture.
This study is the ¢rst successful report of PIR puri¢cation
[10].
3.2. NMR experiments
The structure of PIR was investigated by solution NMR. In
a preliminary NMR study, a 1D experiment was recorded
(data not shown). The 1D spectra showed poor dispersion
of the aliphatic and amide signals, and absence of high ¢eld
shifted methyl groups. In a 2D 15N^1H HSQC experiment
(Fig. 1), although about 70 amide cross-peaks were observed
out of the 74 expected, the very narrow spread of the reso-
nance frequencies for amide protons in both 15N and 1H
dimensions is typical of a largely unfolded protein [25]. The
absence of secondary structure in solution is con¢rmed by the
absence of cross-peaks in the NH^NH region of a 2D NO-
ESY experiment and by the absence of high-¢eld shifted meth-
yl groups (data not shown). They all cluster around random-
coil shifts at 0.92 ppm. Moreover, in a NOESY-HSQC 3D
experiment, no cross-peaks were observed in the NH^NH
region except for two peaks at frequencies of 8.36 ppm/8.01
ppm and 8.22 ppm/7.90 ppm. Consequently, no sequential
attribution was performed due to superimposition, poor dis-
persion of the HK and HL chemical shift and the absence of
sequential or long-distance cross-peaks in 2D and 3D experi-
ments. Taken together, these results strongly suggest that the
PIR domain is largely unstructured in solution [26,27].
To further investigate the conformational state of the PIR
domain, we measured the heteronuclear 15N^1H NOE e¡ects.
Heteronuclear 15N^1H Overhauser enhancements ranged from
34.93 to 30.12 and were modulated by molecular motions:
15N^1H NOEs decreased as the correlation time increased.
These values can thus be used to distinguish rigid from mobile
sites within a protein [22,28]. All heteronuclear NOEs were
negative, ranging from 31 to 33, except for ¢ve peaks which
had higher values ranging from 30.6 to 30.8 (Fig. 2). These
NOE values for 93^95% of the PIR amino acid chain corre-
Fig. 1. 1H^15N HSQC spectra of the 15N-labelled PIR protein. The inset corresponds to a di¡erent level of signal cuto¡ for direct comparison
with Fig. 2.
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spond to movements on the 0.1 ns time scale, which is typical
of an unstructured protein and con¢rms the other NMR re-
sults. Only 5^7% of the amino acids of the PIR protein ex-
hibited slower movement (1 ns time scale). Because disordered
proteins usually acquire folded structure when in complex
with other proteins, this could indicate a nucleation point
for PIR folding.
3.3. In vivo functional studies in X. laevis oocytes
In order to determine whether PIR was biologically active
or not in vivo despite its lack of structure, we have used
X. laevis oocytes, physiologically arrested at the G2 stage of
the ¢rst meiotic prophase, as a model system. The natural
inducer progesterone [29] and some growth factors (IGF-1,
insulin and EGF) [30,31] were used to reinitiate the oocyte
cycle and induce entry into the M phase, thus triggering a
GVBD. Xenopus oocytes react as an all or none system after
activation.
Microinjection of PIR, heated PIR, PIR-SH2, or SH2 do-
mains was processed 1 h prior to insulin stimulation. The
results are summarized in Fig. 3. The injection of 12.5 ng of
PIR-SH2 (0.6 pmol) was su⁄cient to inhibit insulin-induced
GVBD. For the PIR domain, microinjection of 39 ng totally
blocks the GVBD. However the microinjection of 26 ng of
PIR partly blocks the GVBD. This suggests that the minimal
amount of PIR Grb14 needed to suppress insulin-induced
GVBD is close to 30 ng (3.75 pmol). Those amounts are
physiologically relevant. The SH2 domain alone had no e¡ect
on oocyte maturation even when injected in excess.
This indicates that the PIR domain is physiologically active
in vivo despite its lack of structure, and implies that PIR
belongs to the new family of IUPs [32], also called ‘natively
unfolded proteins’. As heat stability is one characteristic of
this family of proteins, PIR was heated to 90‡C for 30 min
and microinjected in oocytes. The heat-treated PIR blocked
equally well as the untreated PIR insulin-induced oocyte mat-
uration. The ability of PIR to retain its inhibitory activity
following extreme heat treatment is consistent with its classi-
¢cation as an IUP.
4. Discussion
The ¢ndings described here constitute the ¢rst detailed
structural and biochemical analyses of the new domain PIR
of Grb14. Here, PIR was expressed and puri¢ed in su⁄cient
quantities for structural studies. Firstly, we have demon-
strated that PIR domain is unstructured in solution as shown
by heteronuclear NMR. This type of NMR experiment is
considered the most versatile and powerful tool to study pro-
teins disorder. Secondly, recombinant PIR and PIR-SH2 do-
Fig. 2. Backbone dynamic of the PIR Grb14 domain. Heteronuclear 15N^1H NOEs spectra of the 15N-labelled PIR protein recorded at 600
MHz and 300 K. In gray are represented NOE e¡ects between 31 and 33, which correspond to an estimated overall correlation time of 0.1
ns. In black are represented NOE e¡ects between 30.6 and 31, which correspond to an estimated overall correlation time of 1 ns. A qualita-
tive analysis of the spectra shows that 5^7% of the PIR domain is less mobile than the rest of the protein.
Fig. 3. E¡ect of the injection of PIR-SH2, PIR and SH2 proteins
on insulin-induced oocyte maturation. Oocytes were microinjected
with increasing amounts of PIR-SH2, PIR, heat-denatured PIR
(90‡C), and SH2 proteins as indicated. Oocyte maturation was as-
sessed by GVBD detection. Results are expressed as the percentage
of GVBD, and are the meanWS.E.M. of two to three independent
experiments.
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mains were shown to be physiologically active in the in vivo
model system Xenopus oocytes. These results strongly suggest
an unstructured functional state of the PIR domain, leading
us to classify it as a new member of the family of IUPs.
IUPs belong to a class of proteins that exhibits little sec-
ondary structure, high £exibility, and low compactness [33^
35]. Consequently, unstructured proteins are characterized by
proteolytic sensitivity and heat stability. We have shown that
heat-treated PIR does not become insoluble and it retains its
ability to inhibit the insulin-induced maturation of oocytes.
The central sequence of PIR is extremely hydrophilic which
is energetically favorable for unstructured proteins. Consistent
with these characteristics, the SH2 domain of Grb10 has been
puri¢ed from the recombinant PIR-SH2 domains using pro-
tease [10], indicating the proteolytic sensitivity of PIR. In the
last 10 years, the number of proteins shown to contain na-
tively unfolded domain(s) under physiological conditions has
increased exponentially. This is mainly due to the develop-
ment of structural genomics. Of all the puri¢ed open reading
frames, around 8% are shown to be unfolded (A. Poupon,
personal communication). Furthermore, ‘natively unfolded
proteins’ are observed to be key regulatory checkpoints of
several signal transduction pathways [34,36]. It has been sug-
gested that the absence of rigid globular structure under phys-
iological conditions might represent a considerable functional
advantage. The large £exibility of natively unfolded proteins
allows them to interact e⁄ciently with several di¡erent targets
[32,34].
The PIR partners described so far are the IR and a new
downstream partner of Grb14, ZIP [14]. A model has been
proposed for the role of ZIP in the Grb14 pathway. ZIP could
act as a functional sca¡old protein connecting protein kinase
Cj (PKCj) to Grb14. ZIP interacts with the V1 domain of
PKCj through its AID domain and with the PIR of Grb14
through its ZZ zinc ¢nger domain [14]. Upon insulin stimu-
lation, PIR binds to the activated IR regulatory kinase loop.
PIR phosphorylation by PKCj via ZIP leads to an increased
Grb14 inhibitory action on IR [14]. The interaction between
PIR and ZIP does not alter the insulin-induced Grb14-IR
interaction. The ability of PIR to bind to diverse ligands
such as the tyrosine kinase loop and ZZ zinc ¢nger requires
a structural £exibility which is consistent with a ‘natively un-
folded’ domain. Nevertheless, unstructured proteins may
undergo some degree of folding upon binding to their partner
[37], a process termed ‘induced folding’. PIR probably ac-
quires structure when complexed with binding partners in its
cellular context as suggested by the 15N{1H}-NOE experi-
ment.
However the target of the Grb7 family of proteins remains
to be elucidated. All three PIR-SH2 domains of the Grb7
family of proteins interact with IR phosphorylated regulatory
kinase loop consisting of residues 1150DFGMTRDIp-
YETDpYpYRKGGKGLLP1172. Structures of active and in-
active state of IR have both been resolved by crystallography
[38,39]. In the inactive state, this loop is not phosphorylated
and IR is autoinhibited by the binding of tyrosine 1162 with
the catalytic site. In the active state, when the three tyrosines
1158 1162 and 1163, are phosphorylated, the kinase loop
Fig. 4. A proposed model for the interaction of PIR-SH2 Grb14 with IR. Superposition on all CK of the unphosphorylated insulin receptor ki-
nase domain (PDB code: 1IRK) colored pink, with the triphosphorylated IRK (PDB code: 1IR3) colored green. The activation loops of IRK
and IR3 are colored purple and light blue, respectively. The backbone of the peptide substrate is brown and AMP-PNP is red. The phospho-
tyrosines, the KC residues of IR3 and the most unmasked amino acids (L1038, I1042 and L1045) upon rearrangement of the IR3P activation
loop are represented. The arrows (blue/orange) indicate the plausible interaction of PIR and SH2 domains of Grb14 with IR.
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undergoes a major conformational change of 30 A[ away from
its original position allowing access to the ATP and to the
substrate binding sites. pY1162 was shown to be the key
phosphotyrosine in stabilizing the kinase loop conformation,
followed by pY1163 and pY1158 [39]. Up to now, it is unclear
if the interaction of PIR-SH2 with IR is mediated by the se-
quence of the loop, a speci¢c structure of this loop, or by
interactions with the residues unmasked by the loop rear-
rangement. Peptide competition experiments have shown
that PIR-IR binding is not a phosphotyrosine-mediated inter-
action [10], which abolishes the ¢rst hypothesis.
From crystallographic studies of IR performed by Hubbard
[39], it has been observed that the rearrangement of the IR
kinase loop upon autophosphorylation reorientates the
C- and N-terminal lobes of the kinase. This movement allows
residues of KC to become solvent-exposed and therefore in-
volved in protein^protein interactions. Consequently it can be
hypothesized that because of the suggested extended form of
PIR domain, this one could take place in the cleft between the
N- and C-terminal lobes of the kinase and could interact with
the solvent-exposed residues of KC (Fig. 4). On this suggested
model of PIR-IR binding, the access of ATP and of the sub-
strate to their respective sites would not be blocked, which is
consistent with the fact that Grb14 behaves as a non-compet-
itive inhibitor. Furthermore, the SH2 domain could stabilize
the PIR-IR binding by interacting with the phosphorylated
regulatory kinase loop. Our oocyte experiments showed that
the inhibitory activity of PIR is six times less e⁄cient than
that of PIR-SH2. This is in good agreement with the reported
Grb14 interaction with IR [8]. The fact that PIR alone inter-
acts less e⁄ciently with IR than PIR-SH2 suggests a role for
the SH2 domain in the stabilization of PIR binding. This
could explain the relative importance of the two domains
PIR and SH2 of the Grb7/10/14 proteins in the interaction
with IR. It has been reported that the SH2 domain is respon-
sible for the binding of Grb7 to the IR, whereas PIR and SH2
are equally important in the Grb10/IR interaction, and PIR is
the main binding domain in the IR-Grb14 interaction.
The SH2 domain of Grb7 displays the same consensus
binding site as Grb2 with the presence of an asparagine at
the +2 position following the phosphotyrosine [40,41]. In ad-
dition the SH2 recognition sequence ‘pYpY’, which corre-
sponds to residues 1162^1163 of the IR activation loop, has
only been reported for Grb2 [42]. This could explain why the
SH2 of Grb7 appears to bind with higher a⁄nity with the
phosphorylated IR than the SH2 of Grb10/14. For the two
other Grbs, the SH2 interaction can su¡er a mismatch mini-
mizing their action as in the Src structure [43], or they can
bind preferentially to pY1158 instead of pY1162pY1163. This
model is supported by the recent study of the crystal structure
of Grb10Q [44] SH2 domain that appears to be a dimer. It has
been proposed that the SH2 dimer binds to the activation
loops of the two tyrosine kinase domains of the IR L subunits
with pY1158 in the canonical phosphotyrosine binding pocket
of each SH2 domain.
Further studies are needed to map the region involved in
the interaction with IR, and in the interaction with ZZ zinc
¢nger domain of the adapter protein ZIP. Identi¢cation of the
speci¢c targets of PIR will be a necessary step to perform
structural studies, and to provide more information in the
signaling speci¢city of the di¡erent members of the Grb7 fam-
ily of proteins.
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